echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Pharmaceutical Marketing > Strong market demand and growth space in the segment of ophthalmic consumables has opened

    Strong market demand and growth space in the segment of ophthalmic consumables has opened

    • Last Update: 2022-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, China's ophthalmic consumables industry has developed rapidly, and the market scale has continued to expand
    .
    According to Frost & Sullivan data, in 2021, China's ophthalmic medical consumables market size will reach 7.
    4 billion yuan, accounting for 47% of the entire ophthalmic medical device market, which is one of
    the largest segments of China's ophthalmic medical device market.
    It is worth noting that ophthalmic consumables such as orthokeratology lenses, intraocular lenses, and decorative color contact lenses have gradually become the key development areas
    of ophthalmic consumables due to their high track growth.
     
    The orthokeratology lens market has great potential for expansion
     
    The full name of orthokeratology lens is rigid breathable contact lens for orthokeratology, commonly known as OK lens
    .
    In October 2021, the National Health Commission issued the "Guidelines for Appropriate Technologies for the Prevention and Control of Myopia in Children and Adolescents (Updated Version)", which pointed out that wearing orthokeratology lenses is one of the scientific correction methods to slow down the development of
    myopia in children and adolescents.
     
    According to data released by the National Health Commission, in 2021, the myopic population in China will be as high as 700 million; In 2018, 2019 and 2020, the incidence of myopia among children and adolescents (primary and secondary school students) was 53.
    6%, 50.
    2% and 52.
    7%,
    respectively.
    With the increasing rate of myopia among adolescents, the need for vision improvement is more urgent, and the market demand for orthokeratology lenses is expected to usher in an order of magnitude growth
    .
    At present, the penetration rate of China's orthokeratology lens market is still low, and the scale of orthokeratology lens market is full
    of growth momentum.
     
    Due to the strict supervision of orthokeratology lenses in China and the high technical barriers of products, there are still few
    orthokeratology lens products that have been approved for marketing in China.
    Domestic orthokeratology lens manufacturers mainly include local enterprises such as OPCOM Vision and Ebonold, as well as foreign-funded enterprises
    such as Euclid Systems Company and South Korea's Lucid Co.
    , Ltd.
    The market share of the above companies ranks high
    in China's orthokeratology lens market.
     
    The strong market demand for orthokeratology lenses helps to expand the revenue space of enterprises, and the revenue capacity of orthokeratology lens enterprises is generally strong
    .
    Taking OPCOM as an example, its financial report for the first half of 2022 shows that the revenue of the company's rigid contact lens segment reached 346 million yuan, a year-on-year increase of 3.
    82%, accounting for more than 50%
    of the company's total revenue in the first half of the year.
     
    There is a vast space for import substitution of intraocular lenses
     
    In recent years, with the increase of people's eye intensity and the intensification of the aging of the population, the number of cataract patients in China has increased
    year by year.
    According to the data of the seventh national census released by the National Bureau of Statistics, China's population aged 60 and over reached 264 million, accounting for 18.
    7%
    of the total population.
    According to the statistics of the Ophthalmology Branch of the Chinese Medical Association, the incidence of cataracts in people aged 60~89 in China is about 80%, and the incidence of cataracts in people over 90 years old is as high as more than
    90%.
    According to this estimate, the number of cataract patients over 60 years old in China may have exceeded 200 million
    .
     
    With the increase in the number of cataract patients, the demand for cataract surgery in China has increased significantly
    .
    According to the prospectus of Albonord, in 2018, China's CSR (cataract surgery rate of one million people) reached 2662, achieving the goal of CSR exceeding 2000 by the end of 2020 as proposed in the "13th Five-Year Plan" National Eye Health Plan (2016-2020) ahead of schedule; In 2012, China's CSR was only 1072
    .
    However, compared with developed countries and regions such as Europe and the United States, China's CSR still has more room for
    improvement.
     
    Among the various eye diseases, the blindness rate of cataract ranks first
    in the world.
    At present, surgical implantation of intraocular lenses to replace cloudy natural lenses is the main means of
    effective treatment of cataracts.
     
    Generally speaking, intraocular lens products on the market are mainly classified from the perspectives of product shape (spherical and aspheric), material properties (soft and hard), and product function (single focus and multifocal
    ).
    At present, intraocular lens products in the domestic market are mainly
    soft monofocal intraocular lenses.
     
    At this stage, China's intraocular lens market is mainly dominated
    by foreign brands.
    According to the data of the "In-depth Research on the Current Status of the Chinese Crystal Industry and Future Investment Research Report (2022-2029)" released by the research report network, the localization rate of intraocular lenses in China is about 20%.

    Local manufacturers of intraocular lenses mainly include Aibonod, Henan Cosmos, Century Kangtai and so on
    .
    At present, most of the domestic intraocular lenses are still in the low-end development stage; International ophthalmic medical device giants such as Alcon, Johnson & Johnson, Bausch & Lomb, and Zeiss have mastered advanced intraocular lens R&D and production technology, occupying a major share of
    the global intraocular lens market.
     
    It is worth noting that at present, many provinces have carried out centralized procurement of intraocular lenses, and the price has dropped significantly
    .
    On the whole, intraocular lens collection is mainly
    based on cost-effective mid-end products.
    At the same time, most of the procurement rules do not require the previous market share of products, which effectively lowers the entry threshold of local enterprises, promotes them to further expand the coverage of terminals, and accelerates the localization process
    .
     
    The decorative color contact lens track is hot
     
    In the field of ophthalmic consumables, decorative color contact lenses have gradually developed into a major segment favored by investment institutions
    due to their good consumer attributes.
    In May 2021, Shanghai Tiluo Medical Device Co.
    , Ltd.
    announced the completion of a series B financing of 420 million yuan, mainly for the research and development and expansion of decorative color contact lenses; in November of the same year, Weimu (Shanghai) Technology Co.
    , Ltd.
    , the parent company of decorative color contact lens brand moody, announced the completion of more than 1 billion yuan of Series C financing, setting a record
    for a single financing in the local decorative color contact lens track.
     
    At the same time, M&A activities in the field of decorative color contact lenses are also frequent
    .
    In March 2021, Abonold announced the acquisition of part of the equity
    of Jiangsu Tianyan Pharmaceutical Technology Co.
    , Ltd.
    , a manufacturer of decorative color contact lenses with independent technical capabilities.
    In April of the same year, Shanghai Haohai Pharmaceutical Technology Development Co.
    , Ltd.
    (hereinafter referred to as Haohai Pharmaceutical) obtained 60% of the equity of Hebei Xinshikang Contact Lens Co.
    , Ltd.
    for 40 million yuan, and obtained the medical device registration certificate
    for 4 soft corneal contact lens products (including decorative color contact lenses).
    However, due to the unsatisfactory effect of enterprise resource integration, Haohai Pharmaceutical announced the transfer of equity
    after that.
     
    At present, the representative enterprises of decorative color contact lenses in China include Haichang Contact Lens Co.
    , Ltd.
    , Jilin Ruilkang Contact Lens Co.
    , Ltd.
    , Jiangsu Vision Medical Equipment Co.
    , Ltd.
    , Jiangsu Hailun Contact Lens Co.
    , Ltd.
    , etc
    .
    Due to certain fashion attributes, decorative color contact lens products change faster than other medical device products
    .
    For domestic production enterprises, continuing to strengthen the construction of the supply chain system and expand production capacity will help keep up with the pace
    of market development.
     
    (Author: Zhongcheng Medical Equipment Research Institute)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.